Prostate Cancer Clinical Trials in Detroit

Showing 81-100 of 314 trials

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

NCT05367440

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.

Metastatic Prostate Cancer

AstraZeneca174 participantsStarted Jun 2022

Detroit, Michigan, United States • Detroit, Michigan, United States • Syracuse, New York, United States +17 more locations

COMPLETEDPhase 1< 1 mile

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

NCT03737370

The objective of this study is to determine the maximum safe dose of Ra-223 in combination with fractionated (split doses) docetaxel when given to subjects and to determine the best administering dose. The study will look at side effects that may happen while taking the combination treatment. A total of approximately 18 subjects will take part in the dose escalation part of the study and an additional 25 subjects will participate in the expansion cohort. This study will be conducted across four centers in the United States.

Metastatic Castrate Resistant Prostate Cancer

Tufts Medical Center43 participantsStarted Jan 2018

Boston, Massachusetts, United States • Boston, Massachusetts, United States • Detroit, Michigan, United States +1 more locations

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Trials in Other Cities

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

InBody Band 3 Fitness Tracker to Improve Health Outcomes and Quality of Life in Black Prostate Cancer Survivors

QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Study of Diagnostic Performance of [18F]CTT1057 in BCR

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

Other Conditions in Detroit